Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fedratinib - Celgene Corporation

Next Previous
Drug Profile

Fedratinib - Celgene Corporation

Alternative Names: FEDR; INREBIC; Inrebic; SAR-302503; TG-101348

Latest Information Update: 18 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TargeGen
  • Developer Bristol-Myers Squibb; Celgene Corporation; Sanofi
  • Class Antifibrotics; Antihaemorrhagics; Antineoplastics; Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis
  • Discontinued Essential thrombocythaemia; Polycythaemia vera; Solid tumours

Most Recent Events

  • 24 Jun 2025 Registered for Myelofibrosis in Japan (PO)
  • 12 Dec 2024 Celgene terminates a phase-III trial in Myelofibrosis (Treatment-experienced) in USA and Canada (PO) due to slow accrual (NCT03755518)
  • 13 Jun 2024 Pharmacodynamics data from the phase III FREEDOM2 trial in Myelofibrosis presented at the 29th Congress of the European Haematology Association 2024 (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top